Although the tissue plasminogen activator (TPA) was approved by the FDA as the only effective drug for a limited group of patients with ischemic stroke in the acute phase because of its narrow therapeutic timeline [11] and well-documented adverse effects, such as increased symptomatic intracerebral hemorrhage [12]. Here, PLAT is linked to intracerebral hemorrhage.